Abstract
If only at a small scale, islet transplantation has successfully addressed what ought to be the primary endpoint of any cell therapy: the functional replenishment of damaged tissue in patients. After years of less-thanoptimal approaches to immunosuppression, recent advances consistently yield long-term graft survival rates comparable to those of whole pancreas transplantation. Limited organ availability is the main hurdle that stands in the way of the widespread clinical utilization of this pioneering intervention. Progress in stem cell research over the past decade, coupled with our decades-long experience with islet transplantation, is shaping the future of cell therapies for the treatment of diabetes. Here we review the most promising avenues of research aimed at generating an inexhaustible supply of insulin-producing cells for islet regeneration, including the differentiation of pluripotent and multipotent stem cells of embryonic and adult origin along the beta cell.
| Original language | English |
|---|---|
| Pages (from-to) | 6876-6884 |
| Number of pages | 9 |
| Journal | World Journal of Gastroenterology |
| Volume | 18 |
| Issue number | 47 |
| DOIs | |
| State | Published - Dec 1 2012 |
Fingerprint
Keywords
- Beta cell differentiation
- Human embryonic stem cells
- Induced pluripotent stem cells
- Islet transplantation
- Mesenchymal stem cells
- Reprogramming
ASJC Scopus subject areas
- Gastroenterology
Cite this
Present and future cell therapies for pancreatic beta cell replenishment. / Dominguez-Bendala, Juan; Ricordi, Camillo.
In: World Journal of Gastroenterology, Vol. 18, No. 47, 01.12.2012, p. 6876-6884.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Present and future cell therapies for pancreatic beta cell replenishment
AU - Dominguez-Bendala, Juan
AU - Ricordi, Camillo
PY - 2012/12/1
Y1 - 2012/12/1
N2 - If only at a small scale, islet transplantation has successfully addressed what ought to be the primary endpoint of any cell therapy: the functional replenishment of damaged tissue in patients. After years of less-thanoptimal approaches to immunosuppression, recent advances consistently yield long-term graft survival rates comparable to those of whole pancreas transplantation. Limited organ availability is the main hurdle that stands in the way of the widespread clinical utilization of this pioneering intervention. Progress in stem cell research over the past decade, coupled with our decades-long experience with islet transplantation, is shaping the future of cell therapies for the treatment of diabetes. Here we review the most promising avenues of research aimed at generating an inexhaustible supply of insulin-producing cells for islet regeneration, including the differentiation of pluripotent and multipotent stem cells of embryonic and adult origin along the beta cell.
AB - If only at a small scale, islet transplantation has successfully addressed what ought to be the primary endpoint of any cell therapy: the functional replenishment of damaged tissue in patients. After years of less-thanoptimal approaches to immunosuppression, recent advances consistently yield long-term graft survival rates comparable to those of whole pancreas transplantation. Limited organ availability is the main hurdle that stands in the way of the widespread clinical utilization of this pioneering intervention. Progress in stem cell research over the past decade, coupled with our decades-long experience with islet transplantation, is shaping the future of cell therapies for the treatment of diabetes. Here we review the most promising avenues of research aimed at generating an inexhaustible supply of insulin-producing cells for islet regeneration, including the differentiation of pluripotent and multipotent stem cells of embryonic and adult origin along the beta cell.
KW - Beta cell differentiation
KW - Human embryonic stem cells
KW - Induced pluripotent stem cells
KW - Islet transplantation
KW - Mesenchymal stem cells
KW - Reprogramming
UR - http://www.scopus.com/inward/record.url?scp=84873912337&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84873912337&partnerID=8YFLogxK
U2 - 10.3748/wjg.v18.i47.6876
DO - 10.3748/wjg.v18.i47.6876
M3 - Article
VL - 18
SP - 6876
EP - 6884
JO - World Journal of Gastroenterology
JF - World Journal of Gastroenterology
SN - 1007-9327
IS - 47
ER -